Merck & Co.
AWARDS
NEWS
On Thursday, the company said the U.S. Food and Drug Administration wants to see additional data beyond the Phase III study announced last year.
Merck said the acquisition adds a pipeline of drug candidates that target a broad range of autoimmune diseases.
Agilent is one of seven health care companies to make the fourth annual list of 100 companies compiled by the publication.
The combination of Keytruda and Lenvima was compared to Lenvima plus everolimus versus Pfizer’s Sutent (sunitinib) for first-line treatment of patients with advanced renal cell carcinoma (RCC).
The U.S. FDA Oncologic Drugs Advisory Committee voted against recommending the drug as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy after surgery, at least for now.
It was a busy week for clinical trial updates. Here’s a look.
JOBS
IN THE PRESS